Cephalexin detailed information

Cephalexin detailed information

Error creating thumbnail: File missing
Clinical data
Pregnancy category	AU: A US: B (No risk in non-human studies)
Routes of administration	Oral
ATC code	J01DB01 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability	Well absorbed
Metabolism	90% excreted unchanged
Elimination half-life	0.9 hours
Excretion	Renal
Identifiers
IUPAC name (6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}- 3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene- 2-carboxylic acid
CAS Number	15686-71-2
PubChem CID	2666
DrugBank	APRD00250
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C16H17N3O4S
Molar mass	347.39 g/mol

WikiDoc Resources for Cephalexin detailed information
Articles
Most recent articles on Cephalexin detailed information Most cited articles on Cephalexin detailed information Review articles on Cephalexin detailed information Articles on Cephalexin detailed information in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cephalexin detailed information Images of Cephalexin detailed information Photos of Cephalexin detailed information Podcasts & MP3s on Cephalexin detailed information Videos on Cephalexin detailed information
Evidence Based Medicine
Cochrane Collaboration on Cephalexin detailed information Bandolier on Cephalexin detailed information TRIP on Cephalexin detailed information
Clinical Trials
Ongoing Trials on Cephalexin detailed information at Clinical Trials.gov Trial results on Cephalexin detailed information Clinical Trials on Cephalexin detailed information at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cephalexin detailed information NICE Guidance on Cephalexin detailed information NHS PRODIGY Guidance FDA on Cephalexin detailed information CDC on Cephalexin detailed information
Books
Books on Cephalexin detailed information
News
Cephalexin detailed information in the news Be alerted to news on Cephalexin detailed information News trends on Cephalexin detailed information
Commentary
Blogs on Cephalexin detailed information
Definitions
Definitions of Cephalexin detailed information
Patient Resources / Community
Patient resources on Cephalexin detailed information Discussion groups on Cephalexin detailed information Patient Handouts on Cephalexin detailed information Directions to Hospitals Treating Cephalexin detailed information Risk calculators and risk factors for Cephalexin detailed information
Healthcare Provider Resources
Symptoms of Cephalexin detailed information Causes & Risk Factors for Cephalexin detailed information Diagnostic studies for Cephalexin detailed information Treatment of Cephalexin detailed information
Continuing Medical Education (CME)
CME Programs on Cephalexin detailed information
International
Cephalexin detailed information en Espanol Cephalexin detailed information en Francais
Business
Cephalexin detailed information in the Marketplace Patents on Cephalexin detailed information
Experimental / Informatics
List of terms related to Cephalexin detailed information

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Cefalexin (INN) (Template:PronEng) or cephalexin (USAN) is a first-generation cephalosporin antibiotic. It is an orally administered agent with a similar antimicrobial spectrum to the intravenous agents cefalotin and cefazolin. It is commonly marketed under the trade name Keflex (Lilly) or Sporidex (Ranbaxy).

Clinical use

Main article: Cephalosporin

Indications

Cefalexin is used to treat urinary tract infections, respiratory tract infections (including sinusitis, otitis media, pharyngitis, tonsillitis and pneumonia, bronchitis), skin and soft tissue infections.

Although it is not generally considered first-line treatment for any indication, it is a useful alternative to penicillins in patients with penicillin hypersensitivity. There is, however, cross-reactivity in 10% of patients with hypersensitivity to penicillins and carbapenems.

Formulations

Cefalexin is commonly marketed as tablets(250 mg and 500 mg), capsules, and powder for oral suspension (125 mg and 250 mg).

It is marketed by generic pharmaceutical manufacturers under a wide range of brand names, including: Apo-Cephalex, Biocef, Cefanox, Ceporex, Cephabos, Cilex, Ialex, Ibilex, Kefexin, Keflet, Keflex, Keforal, Keftab, Keftal, Lopilexin, Novo-Lexin, Ospexin, Zephalexin, Panixine Disperdose and Sporidex.

A version of Keflex 750 mg capsules is marketed for twice-daily dosage, to improve patients' compliance. However, it is not a sustained release formulation, and since it is more expensive than the older strengths, some physicians prescribe three 250 mg capsules to be taken twice daily, as a cheaper alternative.

External links

• MedlinePlus Drug Information: Cephalosporins (systemic) – information from USP DI Advice for the Patient
• FDA Drug Information PDF and Pharmacy Drug Information Insert.

Template:SIB de:Cefalexin th:เซฟาเลกซิน Template:WH Template:WS